Articles

  • Feb 4, 2025 | nature.com | Luciano Costa |Binod Dhakal |Bhagirathbhai Dholaria |Saurabh Chhabra

    Response and progression criteria are necessary for any malignancy to standardize assessment of efficacy across trials. In multiple myeloma (MM), the International Myeloma Working Group (IMWG) established universally accepted criteria for response and progressive disease (PD) anchored on serum and urine paraprotein as primary biomarkers of disease burden [1]. The therapeutic landscape of newly diagnosed MM (NDMM) evolves rapidly.

  • Jan 1, 2025 | jitc.bmj.com | Binod Dhakal |Parameswaran Hari |Saurabh Chhabra |Aniko Szabo

    Immune cell therapies and immune cell engineering Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

  • Dec 27, 2024 | targetedonc.com | Binod Dhakal

    December 27, 2024Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and can be used in widespread community centers. There are more community centers that are staring to use bispecific antibodies, and there is now a much lower rate of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS). Video content above is prompted by the following:What is the future for the treatment of RRMM?

  • Dec 6, 2024 | targetedonc.com | Binod Dhakal

    December 6, 2024Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like talquetamab represent promising new options, particularly for patients with BCMA-refractory disease.

  • Dec 6, 2024 | targetedonc.com | Binod Dhakal

    2 Commerce Drive Cranbury, NJ 08512

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →